Digital growth for pharma manufacturers, PCD franchise brands and healthcare marketers , compliant, credible and conversion-driven. No shortcuts. No hype.
Distributors, retailers and prescribers do weeks of quiet research before the first call. Cold outreach is expensive; category authority is durable. We build the surfaces buyers actually use during that silent evaluation window.
A senior operator experienced in pharma marketing compliance owns every engagement.
A defensible thesis for the brand, therapeutic focus, franchise model, distribution moat.
Content and social systems built specifically for the franchise or distributor decision.
Ad creative that respects regulatory boundaries without becoming sterile.
Therapeutic areas and molecule stories, told with editorial care, not brochureware.
Long-form pieces that rank for the queries distributors and retailers actually search.
Meta, Google and LinkedIn stitched into a nurture funnel with sales, not around them.
Recent pharma and healthcare engagements.
Distributors research franchise partners quietly for weeks before the first call, Skylarr owned none of that surface.
Category-education content across LinkedIn and Meta, tuned to the questions distributors actually ask.
Became the brand distributors mention first when franchise partners ask who they should call.
Deep-expertise engineering house selling into industrial plants, a comparable long-cycle B2B category.
Founder-led LinkedIn + long-form category content, the same playbook translates to pharma B2B.
Became the feed every plant head in India quietly follows. Inbound became the default.
Selling into enterprise buyers who scope by application and cite peer sources, much like pharma prescribing behavior.
Positioned as the category's reference source with editorial content and enterprise-grade collateral.
Became the brand cited in RFPs and scoping calls.
Every pharma engagement runs through the same regulated, compliant discipline.
Category audit, therapeutic focus review, distributor conversations, compliance baseline. The reality check.
Category thesis, franchise story, ICP, messaging architecture, compliance-vetted from day one.
Editorial content, distributor-focused campaigns, sales enablement, all shipping in parallel.
Monthly distributor pipeline reviews, quarterly category refreshes, ongoing compliant publishing.
Three rules govern every pharma engagement we take on.
Great pharma creative is what happens when compliance becomes part of the brief, not the veto.
Franchise growth is a B2B category with its own psychology, treat it like one.
The brands that win pharma long-term win through category education, not campaigns.
“Adcom took the time to actually understand our category. That patience showed up in every asset, compliant, credible, and actually persuasive.”
Dr. Rakesh MalhotraMD, pharma manufacturer
We open a small number of pharma engagements each year, for brands ready to build category authority the compliant way.
Share your current state, we'll come back with a diagnostic and a proposed engagement shape.
Eight questions we are asked on almost every first call. If yours is not here, our lead strategist will answer it within one business day of you reaching out.
We partner with ambitious founders and operators across D2C, fintech, B2B SaaS, wellness, luxury and F&B, primarily in India, the Middle East and the US. Stage matters less to us than ambition: we work with early-stage brands looking to find their growth model and category challengers ready to scale aggressively.
